Characteristics | n | % |
Demographics | ||
Age (range=15–46), mean±SD years | 33.6 | ±8.0 |
Race | ||
(Missing) | 26 | 5.4 |
African American | 248 | 51.9 |
Caucasian | 118 | 24.7 |
Other | 66 | 13.8 |
Asian | 15 | 3.1 |
American Indian/Native Alaskan | 5 | 1.0 |
Positivity of antiphospholipid antibodies (missing=91) | 152 | 31.8 |
Counselling | ||
Specialty of contraception counselling (not mutually exclusive) | ||
Rheumatology | 272 | 56.9 |
OB/GYN | 155 | 32.4 |
Nephrology | 97 | 20.3 |
Family medicine | 48 | 10.0 |
Internal medicine (IM) | 45 | 9.4 |
Other | 40 | 8.4 |
Haematology | 22 | 4.6 |
Pharmacy | 15 | 3.1 |
Number of counselling specialties | ||
0 | 103 | 21.5 |
1 (most common groups (n=): rheumatology (92), OB/GYN (36), family (12), nephrology (11)) | 165 | 34.5 |
2 (rheumatology+OB/GYN (45), rheumatology+nephrology (24)) | 127 | 26.6 |
3 (rheumatology+OB/GYN+nephrology (12), rheumatology+nephrology+IM (9)) | 60 | 12.6 |
4 (rheumatology+OB/GYN+nephrology+other (6)) | 21 | 4.4 |
5 (rheumatology+OB/GYN+nephrology+IM+other) | 1 | 0.2 |
6 (rheumatology+OB/GYN+nephrology+other+haematology+pharmacy) | 1 | 0.2 |
At least 1 counselling specialty | 375 | 78.5 |
At least 2 counselling specialties | 210 | 43.9 |
At least 3 counselling specialties | 83 | 17.4 |
Immunosuppression | ||
Immunosuppression use (not mutually exclusive) | ||
Hydroxychloroquine (HCQ) | 412 | 86.2 |
Mycophenolate mofetil/mycophenolic acid (MMF/MPA) | 143 | 29.9 |
Monoclonal antibody (mAb) (missing=1) | 73 | 15.3 |
Methotrexate (MTX) | 33 | 6.9 |
Cyclophosphamide (CYC) (missing=1) | 10 | 2.1 |
Teratogenic (MMF/MPA, MTX, CYC) | 183 | 38.3 |
Number of immunosuppressive medications | ||
(Missing) | 2 | 0.4 |
0 | 23 | 4.8 |
1 (most common groups (n=): HCQ (230), MMF/MPA (18), mAb (11)) | 266 | 55.6 |
2 (HCQ+MMF/MPA (102), HCQ+mAb (30), HCQ+MTX (18)) | 159 | 33.3 |
3 (HCQ+MMF/MPA+mAb (15), HCQ+mAb+MTX (9)) | 28 | 5.9 |
At least 1 immunosuppressive medication (missing=2) | 453 | 94.8 |
At least 2 immunosuppressive medications (missing=2) | 187 | 39.1 |
Contraception | ||
Type of contraception (n=) | ||
None documented (106) or documented as not using (38) | 144 | 30.1 |
Levonorgestrel IUD (65), Nexplanon (27), copper IUD (10), patch (1) or ring (1) | 104 | 21.8 |
Tubal ligation/salpingectomy (58) or partner vasectomy (6)/orchiectomy (1) | 65 | 13.6 |
Depo-Provera injections (32) or progestin-only OCPs (16) | 48 | 10.0 |
Condoms | 35 | 7.3 |
Abstinence | 32 | 6.7 |
Combination OCPs | 30 | 6.3 |
Currently pregnant (8), menopausal (7) or same sex partner (5) | 20 | 4.2 |
mAb: includes rituximab and belimumab.
IUD, intrauterine device; OB/GYN, obstetrics/gynaecology; OCPs, oral contraceptives.